Показано 0 из 0
Дата |
---|
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.404
|
0.468
|
0.43
|
0.43
|
0.43
|
0.43
|
|
|
|
|
0.412
|
0.46
|
0.43
|
0.43
|
0.43
|
0.43
|
|
|
|
|
0.40
|
0.462
|
0.462
|
0.462
|
0.462
|
0.462
|
|
|
|
|
0.414
|
0.478
|
0.462
|
0.462
|
0.462
|
0.462
|
|
|
|
|
0.434
|
0.484
|
0.462
|
0.462
|
0.462
|
0.462
|
|
|
|
|
0.428
|
0.492
|
0.454
|
0.454
|
0.454
|
0.454
|
|
|
|
|
0.428
|
0.482
|
0.454
|
0.454
|
0.454
|
0.454
|
|
|
|
|
0.412
|
0.46
|
0.458
|
0.458
|
0.458
|
0.458
|
|
|
|
|
0.422
|
0.484
|
0.476
|
0.476
|
0.476
|
0.476
|
|
|
|
|
0.43
|
0.496
|
0.488
|
0.488
|
0.488
|
0.488
|
|
|
|
|
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers.